Medline (MDLN) Q4 FY25 earnings call: guidance and Q&A

What are hospital customers prioritizing in 2026, and what are the company's utilization expectations embedded in guidance?

Hospitals are focused on reimbursement stabilization, value, navigating consolidation (especially to non-acute settings), and resilient supply chains. Medline serves all points of care. Utilization is expected to remain strong but moderate slightly in 2026 due to potential policy impacts.

“health care is going through what I would call a crisis complexity right now. They're dealing with cuts in Medicaid, Medicare. They're worried about the one Big Beautiful Bill. They're concerned about what's happening with the Affordable Care Act.”

asked by Elizabeth Anderson · answered by James Boyle

Can management elaborate on their philosophy for constructing 2026 guidance and how to think about the quarterly cadence of earnings and revenue?

Guidance is realistic, driven by new customer signings (65% of 2025's $2.4B recognized in 2026) and strong, albeit moderated, same-store sales. Supply Chain is expected to grow faster than Medline Brand. Tariffs impact EBITDA. Quarterly seasonality exists due to business days (Q1 one less day, Q4 one more day) and normal business volumes, with Q4 typically stronger.

“we believe confidently we can achieve. We have broken this up into both our sales growth, organic sales growth and adjusted EBITDA.”

asked by David Roman · answered by Michael Drazin

Details on Q4 prime vendor contract wins, areas of strength, and the impact of competitor ownership changes on market dynamics.

Medline achieved a record $2.4 billion in signings in 2025, with strength in Lab & Diagnostics and non-acute. Acute care grew faster due to outsized prime vendor signings. Market conditions (reimbursement, consolidation, competitor uncertainty) remain favorable. Medline commits to $1 billion in annual prime vendor signings, taking advantage of market opportunities.

“We have 29 million square feet in the U.S. We have over $4.5 billion of inventory. We have 99% fill rates. We have the ability to drive value through our brand, which is what they're looking for is cost savings and consistency in terms of throughput and delivery model.”

asked by Patrick Wood · answered by James Boyle

Is there potential for tariffs to be less onerous, what would the company do with any savings, and when will there be more clarity on the impact?

Uncertainty remains regarding tariffs, and Medline will not react immediately, similar to its approach in 2025. The company has a playbook for mitigation and has historically absorbed most of the tariff burden. More clarity is expected from the administration, and Medline will act responsibly as the situation evolves.

“it's important to remember that we either mitigated or absorbed the vast majority of the tariffs. We had a small price increase that we pushed out to the marketplace.”

asked by Matthew Taylor · answered by James Boyle

Clarification on the $35 million tariff impact shift from 2025 to 2026 and its overall effect.

The $35 million tariff impact was a timing matter, capitalized under inventory in 2025 and will be recognized in 2026. While the overall annualized net impact of tariffs for 2026 is estimated at $490 million (down from $525 million due to reduced China/India rates), the incremental headwind for 2026 remains $200 million. The majority of the 2026 tariff burden is expected in the first half.

“That really is just a timing matter. It's capitalized under inventory, will be recognized as a tariff burden in 2026. So it's just shifting $35 million from '25 to '26.”

asked by Andrew Obin · answered by Michael Drazin

What is the observed impact of Medicaid/ACA changes on utilization, and what are Medline's key product areas for expansion?

No change in utilization to date, but a cautious view for the future, especially for rural health. Medline sees significant expansion opportunities in surgical kitting (largest signing year, TAM expansion), Lab & Diagnostics (a $25 billion market), physician office ($9 billion market), and animal health ($4 billion market).

“From a Medline brand, we saw outsized growth in 2025 in our surgical kitting business. It was our largest signing year ever.”

asked by Lisa Gill · answered by James Boyle

What are the best M&A opportunities, and can management share recent successful acquisitions?

Medline is optimistic about M&A, with $1.9 billion in cash for opportunities. The market is ripe for M&A, including non-core assets from competitors. Past successes include DiaMed (physician office distributor), ConvaTec skincare line, Sinclair Dental, and Microtek Surgical. M&A focuses on product categories, channels, and service offerings that fit Medline's strategy.

“we have $1.9 billion in cash on the books, specifically allocated for looking for those M&A opportunities. And I think the market in and of itself is right for M&A.”

asked by Michael Cherny · answered by James Boyle

How do tariff changes logistically and financially impact the company, especially regarding existing inventory?

New tariff rates (e.g., 10% effective yesterday) apply to goods arriving at port. Inventory already on hand (3-5 months for Medline Brand) is capitalized at prior, higher tariff rates. It takes approximately 4-5 months for this higher-tariff inventory to bleed off the P&L, explaining the timing impact from 2025 to 2026.

“if you think about our inventory, we carry more inventory on hand than most of our -- all of our competitors intentionally to provide the best level of service to our customers. And so our Medline Brand inventory is somewhere in the neighborhood of, call it, three to five months on hand.”

asked by Kevin Caliendo · answered by Michael Drazin